



Multidrug Resistance in *Pseudomonas aeruginosa*: Resistance Mechanisms, Epidemiology, and Impact of Resistance on Virulence, Clinical Outcomes, and Treatment

Guest Editors:

Dr. Silvia Gómez-Zorrilla

1. Infectious Diseases

Department, Hospital del Mar,
Passeig Marítim 25-29, 08003
Barcelona, Spain

2. Infectious Pathology and

Antimicrobials Research Group
(IPAR), Institut Hospital del Mar
d'Investigacions Mèdiques (IMIM),
Dr. Aiguader 88, 08003 Barcelona,
Spain

Dr. Cristina Suarez

Consultant in Infectious Diseases
and Clinical Microbiology, Barts
Health NHS Trust, London, UK

Deadline for manuscript
submissions:

closed (31 October 2023)

Message from the Guest Editors

Dear Colleagues,

Pseudomonas aeruginosa is one of the most common nosocomial pathogens, and continuously evolving resistance to multiple antimicrobial agents has become a significant health problem. MDR has been reported as an important determinant of clinical outcomes.

The main objective of this Special Issue is to improve our understanding of the impact of multidrug resistance in *P. aeruginosa* infections. For this purpose, this Special Issue considers all aspects of antibiotic resistance in *P. aeruginosa*. Submissions regarding resistance mechanisms, epidemiology of high-risk clones, the application of molecular diagnostic and genome sequencing, virulence determinants of *P. aeruginosa*, and the biological implications of resistance in virulence of *P. aeruginosa* are encouraged. In addition, manuscripts concerning the clinical and economic burden of multidrug resistance in *P. aeruginosa* infections and MDR *P. aeruginosa* therapeutics approaches are especially welcome.

Keywords: *Pseudomonas aeruginosa*; multidrug resistant; extensively drug-resistant; virulence; biological cost





an Open Access Journal by MDPI

Editor-in-Chief

Prof. Dr. Nicholas Dixon

School of Chemistry and
Molecular Bioscience, University
of Wollongong, Wollongong, NSW
2522, Australia

Message from the Editor-in-Chief

There are very few fields that attract as much attention as scientific endeavor related to antibiotic discovery, use and preservation. The public, patients, scientists, clinicians, policy-makers, NGOs, governments, and supra-governmental organizations are all focusing intensively on it: all are concerned that we use our existing agents more effectively, and develop and evaluate new interventions in time to face emerging challenges for the benefit of present and future generations. We need every discipline to contribute and collaborate: molecular, microbiological, clinical, epidemiological, geographic, economic, social scientific and policy disciples are all key. *Antibiotics* is a nimble, inclusive and rigorous indexed journal as an enabling platform for all who can contribute to solving the greatest broad concerns of the modern world.

Author Benefits

Open Access: free for readers, with article processing charges (APC) paid by authors or their institutions.

High Visibility: indexed within Scopus, SCIE (Web of Science), PubMed, PMC, Embase, CAPlus / SciFinder, and other databases.

Journal Rank: JCR - Q1 (Pharmacology and Pharmacy) / CiteScore - Q1 (General Pharmacology, Toxicology and Pharmaceutics)

Contact Us

Antibiotics Editorial Office
MDPI, Grosspeteranlage 5
4052 Basel, Switzerland

Tel: +41 61 683 77 34
www.mdpi.com

mdpi.com/journal/antibiotics
antibiotics@mdpi.com
X@antibioticsmdpi